The objectives are to (i) determine the current prevalence and intensities
of human schistosomiasis, (ii) study the outcomes of S. haematobium X S. bovis hybrids on snail infectivity, (iii) evaluate the sensitivity of hybrids schistosome populations to PZQ according to parasite genetic introgression
levels, (iv) characterize the frequency of hybrids and their level of genomic introgression.
In this study, we will use an integrative approach combining a genetic monitoring study of the parasite communities infecting human populations in areas with high hybrid prevalence in Senegal before and after
repeated PZQ treatment. Parental and hybrid life history traits (i.e. sensibility to PZQ; host spectrum) will be investigated in controlled laboratory experiments.
Primary Outcome Measures: The cure rate (CR) of the treatments and Egg Reduction Rates (ERR). The CRs will be measured, as the number of fully cured children and the ERRs of each child is the reduction of the number of excreted eggs/ 10 mls of urine, after PZQ treatment.
Secondary Outcome Measures: The frequency of hybrids and the level of genomic introgression between S. bovis and S. haematobium. These outcome measures will be obtained after schistosome molecular analysis.
The frequency of hybrids will be measured by quantification of the numbers of hybrids and pure schistosome miracidia recovered from infected children (pre- and post-PZQ treatment). For hybrid parasites, the genomic introgression level will be measured by SNP's distributed across the parasite genome